Linaclotide Publication Examines Age, Menopausal Status Effects in IBS-C/CIC

A new publication on linaclotide appeared on September 1, 2026, in Neurogastroenterology and Motility. The article, titled "Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies," presents post hoc analyses drawn from earlier Phase 2b and Phase 3 studies of linaclotide. The publication focuses on adults diagnosed with irritable bowel syndrome with constipation or chronic idiopathic constipation. As indicated by the title, the analyses examine how age and age-defined menopausal status relate to outcomes previously observed in these clinical trials. Linaclotide remains an approved compound. This entry reflects only the existence and stated scope of this new publication; no specific findings, efficacy outcomes, or safety results are described here beyond what is contained in the title itself. Readers interested in the detailed methodology, patient subgroups, and reported outcomes should consult the full article through the journal listing. For general background on linaclotide, including its approved uses and mechanism, readers can refer to the compound overview.